EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019

Chie Yamamoto, Masashi Taniguchi, Keitaro Furukawa, Toru Inaba iD, Yui Niiyama, Daisuke Ide, Shinsuke Mizutani iD, Junya Kuroda iD, Yoko Tanino, Keisuke Nishioka, Yohei Watanabe, Koichi Takayama iD und 2 weitere

Viruses · 2024

DOI: 10.3390/v16050718 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Viruses, 2024. Verfasst von Chie Yamamoto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan. Hauptthemen laut MEDLINE: Immunocompromised Host, SARS-CoV-2, Drug Resistance, Viral, Antiviral Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although the coronavirus disease 2019 (COVID-19) pandemic is coming to an end, it still poses a threat to the immunocompromised and others with underlying diseases. Especially in cases of persistent COVID-19, new mutations conferring resistance to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapies have considerable clinical implications. We present a patient who independently acquired a T21I mutation in the 3CL protease after nirmatrelvir exposure. The T21I mutation in the 3CL protease is one of the most frequent mutations responsible for nirmatrelvir resistance. However, limited reports exist on actual cases of SARS-CoV-2 with T21I and other mutations in the 3CL protease. The patient, a 55 year-old male, had COVID-19 during chemotherapy for multiple myeloma. He was treated with nirmatrelvir early in the course of the disease but relapsed, and SARS-CoV-2 with a T21I mutation in the 3CL protease was detected in nasopharyngeal swab fluid. The patient had temporary respiratory failure but later recovered well. During treatment with remdesivir and dexamethasone, viruses with the T21I mutation in the 3CL protease showed a decreasing trend during disease progression while increasing during improvement. The impact of drug-resistant SARS-CoV-2 on the clinical course, including its severity, remains unknown. Our study is important for examining the clinical impact of nirmatrelvir resistance in COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunocompromised HostSARS-CoV-2Drug Resistance, ViralAntiviral AgentsCOVID-19HumansMiddle AgedMaleMutationMultiple MyelomaCoronavirus 3C ProteasesCOVID-19 Drug TreatmentAlanine

Stichwörter der Autor:innen

SARS-CoV-2antiviral drug resistanceimmunocompromised hostnirmatrelvir

Substanzen

Antiviral AgentsCoronavirus 3C ProteasesAlanine

Autor:innen und Institutionen

  • Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
  • Department of Infectious Disease, Kyoto City Hospital, Kyoto 604-8845, Japan.
  • Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
  • Department of Infectious Diseases, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.

ORCID-Profile: Toru Inaba, Shinsuke Mizutani, Junya Kuroda, Koichi Takayama, Yoko Nukui

Zitieren

APA

Yamamoto, C., Taniguchi, M., Furukawa, K., Inaba, T., Niiyama, Y., Ide, D., Mizutani, S., Kuroda, J., Tanino, Y., Nishioka, K., Watanabe, Y., Takayama, K., Nakaya, T., & Nukui, Y. (2024). Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019. Viruses. https://doi.org/10.3390/v16050718

Vancouver

Yamamoto C, Taniguchi M, Furukawa K, Inaba T, Niiyama Y, Ide D, et al. Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019. Viruses. 2024. doi:10.3390/v16050718

BibTeX
@article{Yamamoto2024,
  author = {Yamamoto, Chie and Taniguchi, Masashi and Furukawa, Keitaro and Inaba, Toru and Niiyama, Yui and Ide, Daisuke and Mizutani, Shinsuke and Kuroda, Junya and Tanino, Yoko and Nishioka, Keisuke and Watanabe, Yohei and Takayama, Koichi and Nakaya, Takaaki and Nukui, Yoko},
  title = {Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16050718}
}
Kostenlos starten →